Home › NDC Lookup › J-codes › J2183
J2183

J2183 – Inj meropenem (wg crit care) · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 100 MG $1.408/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J2183 summary

J2183 is a HCPCS Level II J-code used to bill meropenem (wg crit care), billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J2183: Meropenem(J2183)

Code J2183 Billing unit 100 MG Payment limit $1.408/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ2183
DescriptorInj meropenem (wg crit care)
Billing unit100 MG
Payment limit / unit$1.408
Est. ASP / unit$1.328 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

💊 About Meropenem DRUG GUIDE

Meropenem for injection is used intravenously to treat three types of serious bacterial infections.

For adults and children 3 months and older, it treats complicated skin and skin structure infections.

For adults and children of all ages, it treats complicated intra-abdominal infections such as complicated appendicitis and peritonitis.

Bacterial meningitis (infection of the lining around the brain and spinal cord) in children 3 months and older is also an approved use.Meropenem should only be used when a bacterial infection is proven or strongly suspected.

Read the full Meropenem drug guide →
Clinical overview from our editorial drug guide for Meropenem. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$1.408
Est. ASP / unit
$1.328 est.
Est. after 2% sequester
$1.380
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J2183 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J2183 WITH EST. MEDICARE PAY

2 NDCs map to J2183. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($1.408/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
44567-0402-06 Meropenem 2 g/1 INJECTION, POWDER, FOR SOLUTION WG 6 VIAL in 1 CARTON (44567-402-06) / 1 INJ... 2 g/1 120 $168.96 — ● Active CMS + PDAC
72078-0081-06 Meropenem 2 g/1 INJECTION Mylan 6 INJECTION in 1 CARTON (72078-081-06) 2 g/1 120 $168.96 — ● Active CMS + PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend
$30.9K
Claims
460
Beneficiaries
315
Spend / beneficiary
$98.21
Spend / claim
$67.25
Where J2183 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #755 of 918
#750 CEFAZOLIN SODIUM(J06... J0688 $35.5K #751 AFLURIA (90657)* 90657 $35.4K #752 ARGATROBAN-0.9% NACL... J0883 $34.9K #753 NAFCILLIN SODIUM J2290 $34.2K #754 LEVOLEUCOVORIN CALCI... J0641 $32.9K #755 MEROPENEM(J2183) J2183 $30.9K #756 HEPAGAM B(J1571) J1571 $30.4K #757 BUPIVACAINE HCL* J0665 $28.1K #758 HYLENEX J3473 $28.1K #759 PREMARIN J1410 $27.2K #760 CALCIUM GLUCONATE-NA... J0612 $26K
Total claims — #651 of 918
#646 MIRCERA J0888 473 #647 GAMASTAN J1460 473 #648 ACETADOTE* J0132 471 #649 BUTORPHANOL TARTRATE J0595 470 #650 BRIXADI(J0578) J0578 466 #651 MEROPENEM(J2183) J2183 460 #652 HYLENEX J3473 456 #653 LEVOTHYROXINE SODIUM... J0651 455 #654 GIVLAARI J0223 453 #655 ACETAMINOPHEN(J0136) J0136 450 #656 ADRENALIN(J0165)* J0165 448

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2025 (Q1-Q4) $30.9K 315 460 $98.21 $67.25
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$97.88
Medicare paid
$44.85
Submitted services
8,840
Denial rate
99.3%
Allowed / service
$1.63
Submitted charges
$43.8K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

📊 What bills under J2183

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
Meropenem 4
NDC products by labeler
WG Critical Care, LLC 3
Mylan Institutional LLC 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J2183 billing FAQ

What is HCPCS code J2183?
J2183 is a HCPCS Level II J-code used to bill Inj meropenem (wg crit care) under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2183?
One unit of J2183 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J2183 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2183?
The Medicare Part B payment limit is $1.408 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $1.380 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2183?
2 NDCs currently map to J2183 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2183 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.